THE CONTROL OF THE ANTIBODY ISOTYPE RESPONSE TO RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS GP120 ANTIGEN BY ADJUVANTS

被引:85
作者
BOMFORD, R
STAPLETON, M
WINSOR, S
MCKNIGHT, A
ANDRONOVA, T
机构
[1] WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND
[2] INST CANC RES, LONDON SW3 6JB, ENGLAND
[3] MM SHEMYAKIN BIOORGAN CHEM INST, MOSCOW 117871, USSR
关键词
D O I
10.1089/aid.1992.8.1765
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Both saponin and muramyl dipeptide (MDP) formulated with a squalane-in-water emulsion of large particle size prepared with a vortex mixer were superior to Al(OH)3 as adjuvants for HIV gp120 in mice. All the adjuvants induced IgG1 antibody, but saponin elicited the highest titers of IgG2a. The secretion of interleukin-5 (IL-5) and interferongamma (IFNgamma) by lymph node cells cultured in vitro with gp120 was studied. All the cultures secreted IL-5, but only those from saponin-immunized mice produced IFNgamma, suggesting that saponin is capable of activating both the Th1 and TH2 T-cell subsets. The titers of neutralizing antibodies were low with both MDP and saponin, and they occurred in mice which were also positive for antibodies against a V3 loop peptide. Glucosaminylmuramyl dipeptide (GMDP) which is less pyrogenic than MDP and a nonpyrogenic analog GMDPA, displayed equivalent adjuvant activity to MDP. The level and isotype composition of antibodies induced by GMDP in combination with squalane emulsions depended on the dimension of the emulsion particles. With a large (2500 nm) particle size the response was confined to IgG1 in Balb/c mice, but when this was reduced to 150 nm by sonication the antibody response was increased and relatively high levels of IgG2a appeared in some mice.
引用
收藏
页码:1765 / 1771
页数:7
相关论文
共 23 条
[1]   PRIMING OF CD4+ T-CELLS SPECIFIC FOR CONSERVED REGIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS GLYCOPROTEIN GP120 IN HUMANS IMMUNIZED WITH A RECOMBINANT ENVELOPE PROTEIN [J].
ABRIGNANI, S ;
MONTAGNA, D ;
JEANNET, M ;
WINTSCH, J ;
HAIGWOOD, NL ;
SHUSTER, JR ;
STEIMER, KS ;
CRUCHAUD, A ;
STAEHELIN, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (16) :6136-6140
[2]   AN ADJUVANT FORMULATION THAT SELECTIVELY ELICITS THE FORMATION OF ANTIBODIES OF PROTECTIVE ISOTYPES AND OF CELL-MEDIATED-IMMUNITY [J].
ALLISON, AC ;
BYARS, NE .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (02) :157-168
[3]  
ANDRONOVA T, 1992, NATURAL SYNTHETIC IM
[4]   PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].
BERMAN, PW ;
GREGORY, TJ ;
RIDDLE, L ;
NAKAMURA, GR ;
CHAMPE, MA ;
PORTER, JP ;
WURM, FM ;
HERSHBERG, RD ;
COBB, EK ;
EICHBERG, JW .
NATURE, 1990, 345 (6276) :622-625
[5]   ADJUVANT FORMULATION FOR USE IN VACCINES TO ELICIT BOTH CELL-MEDIATED AND HUMORAL IMMUNITY [J].
BYARS, NE ;
ALLISON, AC .
VACCINE, 1987, 5 (03) :223-228
[6]   CYTOKINES AND IG SWITCHING - EVOLUTIONARY DIVERGENCE BETWEEN MICE AND HUMANS [J].
CALLARD, RE ;
TURNER, MW .
IMMUNOLOGY TODAY, 1990, 11 (06) :200-203
[7]   VACCINE PROTECTION OF RHESUS MACAQUES AGAINST SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION [J].
CARLSON, JR ;
MCGRAW, TP ;
KEDDIE, E ;
YEE, JL ;
ROSENTHAL, A ;
LANGLOIS, AJ ;
DICKOVER, R ;
DONOVAN, R ;
LUCIW, PA ;
JENNINGS, MB ;
GARDNER, MB .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (11) :1239-1246
[8]   VACCINE PROTECTION AGAINST SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION [J].
DESROSIERS, RC ;
WYAND, MS ;
KODAMA, T ;
RINGLER, DJ ;
ARTHUR, LO ;
SEHGAL, PK ;
LETVIN, NL ;
KING, NW ;
DANIEL, MD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (16) :6353-6357
[9]   ISOTYPIC RESTRICTION OF THE ANTIBODY-RESPONSE TO HUMAN IMMUNODEFICIENCY VIRUS [J].
KHALIFE, J ;
GUY, B ;
CAPRON, M ;
KIENY, MP ;
AMEISEN, JC ;
MONTAGNIER, L ;
LECOCQ, JP ;
CAPRON, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1988, 4 (01) :3-9
[10]   FORMULATION OF VACCINE ADJUVANT MURAMYLDIPEPTIDES .3. PROCESSING OPTIMIZATION, CHARACTERIZATION, AND BIOACTIVITY OF AN EMULSION VEHICLE [J].
LIDGATE, DM ;
FU, RC ;
BYARS, NE ;
FOSTER, LC ;
FLEITMAN, JS .
PHARMACEUTICAL RESEARCH, 1989, 6 (09) :748-752